Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Mirae Asset Global Investments Co. Ltd. lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMSGet Rating) by 12.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,066 shares of the company’s stock after selling 36,987 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.12% of Hims & Hers Health worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Redpoint Management LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $68,095,000. Forerunner Ventures Management LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $63,908,000. Hawk Ridge Capital Management LP grew its stake in shares of Hims & Hers Health by 124.0% during the fourth quarter. Hawk Ridge Capital Management LP now owns 309,600 shares of the company’s stock worth $2,028,000 after acquiring an additional 171,409 shares during the last quarter. Swiss National Bank grew its stake in shares of Hims & Hers Health by 7.9% during the first quarter. Swiss National Bank now owns 185,000 shares of the company’s stock worth $986,000 after acquiring an additional 13,500 shares during the last quarter. Finally, PEAK6 Investments LLC boosted its position in Hims & Hers Health by 18.3% in the fourth quarter. PEAK6 Investments LLC now owns 138,866 shares of the company’s stock valued at $910,000 after buying an additional 21,526 shares during the last quarter. Hedge funds and other institutional investors own 57.22% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, Director Jules A. Maltz bought 75,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, June 14th. The stock was acquired at an average cost of $3.66 per share, with a total value of $274,500.00. Following the purchase, the director now directly owns 125,000 shares in the company, valued at approximately $457,500. The acquisition was disclosed in a filing with the SEC, which is available at this link. In other Hims & Hers Health news, Director Jules A. Maltz bought 75,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, June 14th. The stock was acquired at an average cost of $3.66 per share, with a total value of $274,500.00. Following the purchase, the director now directly owns 125,000 shares in the company, valued at approximately $457,500. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Lynne Chou O’keefe sold 10,045 shares of the company’s stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $4.35, for a total value of $43,695.75. The disclosure for this sale can be found here. Corporate insiders own 35.22% of the company’s stock.

Hims & Hers Health Trading Down 5.6 %

Shares of NYSE:HIMS opened at $6.02 on Friday. Hims & Hers Health, Inc. has a 12-month low of $2.72 and a 12-month high of $9.35. The company has a market capitalization of $1.23 billion, a PE ratio of -14.68 and a beta of 0.49. The business has a 50 day moving average of $5.76 and a two-hundred day moving average of $4.92.

Hims & Hers Health (NYSE:HIMSGet Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $113.60 million during the quarter, compared to the consensus estimate of $103.89 million. Hims & Hers Health had a negative return on equity of 23.24% and a negative net margin of 22.22%. Hims & Hers Health’s revenue for the quarter was up 89.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.08) earnings per share. Equities research analysts predict that Hims & Hers Health, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Credit Suisse Group upped their target price on Hims & Hers Health from $7.00 to $8.00 and gave the company an “outperform” rating in a research report on Wednesday, August 10th. Guggenheim upped their target price on Hims & Hers Health to $12.00 in a research report on Monday, August 15th. Piper Sandler dropped their target price on Hims & Hers Health from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, May 26th. Citigroup dropped their target price on Hims & Hers Health from $9.00 to $6.00 in a research report on Tuesday, May 10th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $7.00 to $8.00 in a research report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.43.

Hims & Hers Health Profile

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Read More

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMSGet Rating).



Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *